Ken Griffin Novo Cure LTD Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$15.61 - $23.34 $429,275 - $641,850	27,500 Added 62.79%	71,300 $1.11 Million
Q2 2024 Aug 14, 2024	SELL	$11.83 - $24.05 $1.39 Million - $2.83 Million	-117,700 Reduced 72.88%	43,800 $750,000
Q1 2024 May 15, 2024	BUY	$12.42 - $17.29 $963,792 - $1.34 Million	77,600 Added 92.49%	161,500 $2.52 Million
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $209,244 - $296,664	18,800 Added 28.88%	83,900 $1.25 Million
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $899,554 - $2.36 Million	55,700 Added 592.55%	65,100 $1.05 Million
Q2 2023 Aug 14, 2023	SELL	$40.29 - $82.51 $2.4 Million - $4.91 Million	-59,500 Reduced 86.36%	9,400 $390,000
Q1 2023 May 15, 2023	SELL	$56.44 - $118.81 $6.17 Million - $13 Million	-109,300 Reduced 61.34%	68,900 $4.14 Million
Q4 2022 Feb 14, 2023	BUY	$63.98 - $85.37 $1.43 Million - $1.9 Million	22,300 Added 14.3%	178,200 $13.1 Million
Q3 2022 Nov 14, 2022	SELL	$67.99 - $89.57 $2.11 Million - $2.78 Million	-31,000 Reduced 16.59%	155,900 $11.8 Million

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.07B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.